[1]刘志坚,刘海燕,宿抱玉.阿帕替尼联合多西他赛治疗晚期非小细胞肺癌疗效和安全性的Meta分析[J].医学信息,2021,34(07):10-14.[doi:10.3969/j.issn.1006-1959.2021.07.003]
　LIU Zhi-jian,LIU Hai-yan,SU Bao-yu.Meta-analysis of the Efficacy and Safety of Apatinib Combined with Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2021,34(07):10-14.[doi:10.3969/j.issn.1006-1959.2021.07.003]
点击复制

阿帕替尼联合多西他赛治疗晚期非小细胞肺癌疗效和安全性的Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年07期
页码:
10-14
栏目:
出版日期:
2021-04-01

文章信息/Info

Title:
Meta-analysis of the Efficacy and Safety of Apatinib Combined with Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer
文章编号:
1006-1959（2021）07-0010-05
作者:
刘志坚; 刘海燕; 宿抱玉
（1.山东第一医科大学/山东省医学科学院，山东 泰安 271000； 2.山东第一医科大学第二附属医院肿瘤科，山东 泰安 271000）
Author(s):
LIU Zhi-jian; LIU Hai-yan; SU Bao-yu
(1.Shandong First Medical University/Shandong Academy of Medical Sciences,Tai’an 271000,Shandong,China; 2.Department of Oncology,the Second Affiliated Hospital of Shandong First Medical University,Tai’an 271000,Shandong,China)
关键词:
阿帕替尼; 多西他赛; 晚期非小细胞肺癌
Keywords:
Apatinib; Docetaxel; Advanced non-small cell lung cancer
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2021.07.003
文献标志码:
A
摘要:
目的 分析阿帕替尼联合多西他赛治疗晚期非小细胞肺癌的疗效及安全性，为临床实践应用提供循证学参考。方法 通过中国期刊文献数据库（CNKI）、万方数据库、维普数据库、中国生物医学文献数据库（CBM）、PubMed、Cochrane Library、EMbase数据库，检索所有关于阿帕替尼联合多西他赛治疗晚期非小细胞肺癌的文献，其中实验组为阿帕替尼联合多西他赛治疗，对照组为常规化疗治疗，提取相关资料并质量评价后，采用RevMan 5.3软件进行Meta分析。结果 本研究共纳入11篇文献。Meta分析结果表示，阿帕替尼联合多西他赛组治疗晚期NSCLC的ORR优于多西他赛单药治疗组（RR=1.77；95CI：1.46~2.15；P＜0.0001）；阿帕替尼联合多西他赛组治疗晚期NSCLC的DCR同样优于多西他赛单药治疗组（RR=1.49；95CI：1.33~1.66；P＜0.0001）；阿帕替尼联合多西他赛较多西他赛组高血压、消化道反应、手足综合征及出血发生率较高，但绝大多数为一级及二级不良反应，无患者因发生不良反应退出研究。结论 阿帕替尼联合多西他赛治疗晚期NSCLC有更优异的近期疗效，不良反应总体可耐受。
Abstract:
Objective To analyze the efficacy and safety of apatinib combined with docetaxel in the treatment of advanced non-small cell lung cancer and provide evidence-based reference for clinical practice.Methods Through China Journal Literature Database (CNKI), Wanfang Database, VIP Database, China Biomedical Literature Database (CBM), PubMed, Cochrane Library, EMbase, Search all the literatures on the treatment of apatinib combined with docetaxel in the treatment of advanced non-small cell lung cancer. The experimental group is the treatment of apatinib combined with docetaxel.The control group was treated with conventional chemotherapy. After extracting relevant data and evaluating the quality,RevMan 5.3 software was used for Meta analysis.Results A total of 11 articles were included in this study.The results of meta-analysis showed that the ORR of apatinib combined with docetaxel in advanced NSCLC was better than that of docetaxel alone (RR=1.77;95CI:1.46-2.15;P＜0.0001).The DCR of apatinib combined with docetaxel in the treatment of advanced NSCLC was also superior to that of docetaxel alone (RR=1.49;95CI:1.33-1.66;P＜0.0001).Apatinib combined with docetaxel was more common in the sitoxel group, and the incidence of hypertension, gastrointestinal reactions, hand-foot syndrome and bleeding was higher.However, most of them were first-level and second-level adverse reactions, and no patients withdrew from the study due to adverse reactions.Conclusion Apatinib combined with docetaxel has a better short-term efficacy in advanced NSCLC, with overall tolerance to adverse reactions.

参考文献/References:

[1]Jacobsen MM,Silverstein SC,Quinn M,et al.Timeliness of access to lung cancer diagnosis and treatment： a scoping literature review[J].Lung Cancer,2017(112):156-164. [2]Hicklin DJ,Ellis LM.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J].Journal of Clinical Oncology,2005,23(5):1011-1027. [3]Roviello G,Ravelli A,Polom K,et al.Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer[J].Cancer Lett,2016,372(2):187-191. [4]尹建宏.阿帕替尼联合化疗治疗晚期非小细胞肺癌的临床效果[J].河南医学研究,2019,28(5):872-874. [5]王永莎,范娟,傅少志,等.阿帕替尼联合紫杉醇不同时序给药治疗肺癌的实验[J].肿瘤防治研究,2016,43(7):560-565. [6]郭运杰,井小会.多西他赛联合阿帕替尼二线治疗非鳞癌非小细胞肺癌的有效性及安全性分析[J].中国肿瘤临床2017,44(11):544-546. [7]刘旭阳,郑静.阿帕替尼联合多西他赛二线化疗治疗晚期非鳞非小细胞肺癌的疗效观察[J].实用心脑肺血管病杂志,2018,6(26):104-107. [8]尚可,胡若洋,胡继德.阿帕替尼联合多西他赛二线以上治疗对晚期非小细胞肺癌患者CEA、SCC及CA125的影响[J].实用癌症杂志,2019,34(7):1172-1175. [9]田丹,尚学琴,李新.阿帕替尼联合多西他赛二线治疗晚期非小细胞肺癌近期疗效及预后分析[J].中国煤炭工业医学杂志,2018,21(5):483-487. [10]徐芳.阿帕替尼联合多西他赛针对一线治疗失败的晚期非鳞非小细胞肺癌临床疗效分析[J].中国处方药,2019,16(8):58-59. [11]岳兴家,许加华,张洪洋,等.多西他赛联合阿帕替尼在非鳞癌非小细胞肺癌二线治疗中的疗效[J].中国老年学杂志,2019,4(39):1849-1852. [12]邓丽华,陆颖.甲磺酸阿帕替尼联合多西他赛治疗晚期非小细胞肺癌的疗效[J].医学理论与实践,2019,32(23):3828-3829. [13]吴军,戴明.多西他赛联合阿帕替尼二线治疗非鳞癌非小细胞肺癌的疗效观察[J].中国肿瘤临床与康复,2020,27(3):307-311. [14]杨宏山,李俊,贾晓燕.阿帕替尼治疗晚期非小细胞肺癌的近期疗效观察[J].国际医药卫生导报,2019,25(22):3749-3752. [15]姚华.分析阿帕替尼联合多西他赛二线化疗治疗晚期非鳞非小细胞肺癌的疗效[J].医药临床,2020,2(4):128. [16]俞昌赫.多西他赛联合阿帕替尼二线治疗进展期非小细胞肺癌的临床研究[J].中国临床药理学杂志,2019,35(22):2812-2818. [17]Roviello G,Ravelli A,Polom K,et al.Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer[J].Cancer Lett,2016,372(2):187-191. [18]Zhang L,Shi M,Huang C,et al.A phaseⅡ,multicenter,placebocontrolled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer( NSCLC) after two previous treatment regimens[J].J Clin Oncol,2012,30(15_suppl):7548. [19]王传翠,朱文,王智刚.Lemur酪氨酸激酶3对肺鳞癌SKMES-1细胞增殖侵袭的影响[J].中华实验外科杂志,2018,35(9):1774-1774. [20]赵颖,王芮.抗肿瘤药物多西他赛研究进展[J].中国药业,2014,23(10):87-89.

相似文献/References:

[1]朱淑娟.多西他赛在控制晚期非小细胞肺癌恶性胸腔积液的 疗效和安全性评估[J].医学信息,2018,31(15):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
　ZHU Shu-juan.Efficacy and Safety of Docetaxel in the Control of Malignant Pleural Effusion in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,31(07):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
[2]李 光.替吉奥联合阿帕替尼治疗晚期胰腺癌的疗效分析[J].医学信息,2018,31(16):87.[doi:10.3969/j.issn.1006-1959.2018.16.025]
　LI Guang.Therapeutic Effect of Tiggio Combined with Apatinib in the Treatment of Advanced Pancreatic Cancer[J].Medical Information,2018,31(07):87.[doi:10.3969/j.issn.1006-1959.2018.16.025]
[3]张晓玲.替吉奥联合多西他赛治疗转移性乳腺癌的临床疗效观察[J].医学信息,2018,31(20):128.[doi:10.3969/j.issn.1006-1959.2018.20.038]
　ZHANG Xiao-ling.Clinical Observation of Tegafur,Gimeracil and Oteracil Porassium Capsules Combined with Docetaxel in the Treatment of Metastatic Breast Cancer[J].Medical Information,2018,31(07):128.[doi:10.3969/j.issn.1006-1959.2018.20.038]
[4]张伟娜,黄晓华.多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌患者的临床疗效评价[J].医学信息,2019,32(08):154.[doi:10.3969/j.issn.1006-1959.2019.08.047]
　ZHANG Wei-na,HUANG Xiao-hua.Clinical Evaluation of Docetaxel Combined with Lobaplatin in the Treatment of Patients with Advanced Ovarian Cancer[J].Medical Information,2019,32(07):154.[doi:10.3969/j.issn.1006-1959.2019.08.047]
[5]刘 鑫,张劲松,王海峰.转移性激素敏感性前列腺癌研究进展[J].医学信息,2019,32(15):30.[doi:10.3969/j.issn.1006-1959.2019.15.011]
　LIU Xin,ZHANG Jin-song,WANG Hai-feng.Research Progress on the Metastatic Hormone-sensitive Prostate Cancer[J].Medical Information,2019,32(07):30.[doi:10.3969/j.issn.1006-1959.2019.15.011]
[6]付大鹏.多西他赛联合表柔比星新辅助化疗治疗乳腺癌的效果[J].医学信息,2020,33(05):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
　FU Da-peng.Evaluation of Docetaxel Combined with Epirubicin Neoadjuvant Chemotherapy for Breast Cancer[J].Medical Information,2020,33(07):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
[7]王启平,兰安宁,吴晓峰.低剂量地塞米松对乳腺癌化疗不良反应的影响[J].医学信息,2020,33(14):146.[doi:10.3969/j.issn.1006-1959.2020.14.045]
　WANG Qi-ping,LAN An-ning,WU Xiao-feng.Effect of Low-dose Dexamethasone on Adverse Reactions of Chemotherapy in Breast Cancer[J].Medical Information,2020,33(07):146.[doi:10.3969/j.issn.1006-1959.2020.14.045]
[8]王红艳,潘 利.自拟抑癌汤联合阿帕替尼治疗对中晚期胃癌患者的疗效及对血清CEA、CA199的影响[J].医学信息,2021,34(14):166.[doi:10.3969/j.issn.1006-1959.2021.14.047]
　WANG Hong-yan,PAN Li.Efficacy of Self-made Anti Cancer Soup Combined with Apatinib on Patients with Middle and Advanced Gastric Cancer and Its Effect on Serum CEA,CA199[J].Medical Information,2021,34(07):166.[doi:10.3969/j.issn.1006-1959.2021.14.047]
[9]何显阳,刘方文,黄云英,等.多西他赛联合顺铂新辅助化疗对非小细胞肺癌治疗中相关肿瘤标记物的影响[J].医学信息,2021,34(23):165.[doi:10.3969/j.issn.1006-1959.2021.23.050]
　HE Xian-yang,LIU Fang-wen,HUANG Yun-ying,et al.Effect of Docetaxel Combined with Cisplatin Neoadjuvant Chemotherapy on Related Tumor Markers in the Treatment of Non-small Cell Lung Cancer[J].Medical Information,2021,34(07):165.[doi:10.3969/j.issn.1006-1959.2021.23.050]
[10]张书林,黄盛源,刘忠林,等.吉西他滨和多西他赛联合顺铂治疗晚期非小细胞肺鳞癌的效果比较[J].医学信息,2021,34(24):141.[doi:10.3969/j.issn.1006-1959.2021.24.036]
　ZHANG Shu-lin,HUANG Sheng-yuan,LIU Zhong-lin,et al.Comparison of Gemcitabine and Docetaxel Combined with Cisplatin in the Treatment of Advanced Non-small Cell Lung Squamous Cell Carcinoma[J].Medical Information,2021,34(07):141.[doi:10.3969/j.issn.1006-1959.2021.24.036]
[11]杨 欢,朱 梅,张改琴,等.多西他赛腹腔灌注加静脉化疗及口服替吉奥联合阿帕替尼治疗胃癌腹膜转移患者的效果[J].医学信息,2022,35(19):121.[doi:10.3969/j.issn.1006-1959.2022.19.034]
　YANG Huan,ZHU Mei,ZHANG Gai-qin,et al.Effect of Docetaxel Intraperitoneal Perfusion Plus Intravenous Chemotherapy and Oral Tegafur Combined with Apatinib in the Treatment of Gastric Cancer Patients with Peritoneal Metastasis[J].Medical Information,2022,35(07):121.[doi:10.3969/j.issn.1006-1959.2022.19.034]

更新日期/Last Update: 1900-01-01